Ironwood Pharmaceuticals, Inc. Class A
(NASDAQ : IRWD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-0.89%178.380.4%$141.72m
PRGOPerrigo Co. Plc
-0.43%73.586.8%$92.39m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-3.01%164.986.8%$81.58m
JAZZJazz Pharmaceuticals Plc
-0.35%163.782.2%$72.75m
MNKMallinckrodt Plc
-0.40%29.6421.1%$63.36m
ENDPEndo International Plc
-1.41%16.128.9%$58.85m
SAGESAGE Therapeutics, Inc.
-0.70%146.019.6%$38.82m
PTLAPortola Pharmaceuticals, Inc.
-2.20%27.557.7%$38.13m
UTHRUnited Therapeutics Corporation
-1.20%122.7414.4%$37.56m
CTLTCatalent Inc
-0.81%42.642.4%$37.33m
ICPTIntercept Pharmaceuticals, Inc.
-3.94%114.1718.7%$34.87m
SUPNSupernus Pharmaceuticals, Inc.
-2.00%48.906.2%$31.11m
ZGNXZogenix, Inc.
-0.30%49.1510.0%$28.09m
PCRXPacira Pharmaceuticals, Inc.
-2.89%50.5010.6%$27.95m
ICLRICON Plc
0.17%150.254.2%$27.04m

Company Profile

Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.